Paradigm Biopharmaceuticals Limited (PBIGF)
USD 0.13
(-62.83%)
USD 0.13
(-62.83%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 239.33 Thousand AUD | -29.95% |
| 2023 | 341.66 Thousand AUD | -44.6% |
| 2022 | 616.66 Thousand AUD | -17.98% |
| 2021 | 751.84 Thousand AUD | -13.95% |
| 2020 | 873.68 Thousand AUD | 2287.85% |
| 2019 | 36.58 Thousand AUD | 0.0% |
| 2018 | 36.58 Thousand AUD | 0.0% |
| 2017 | 36.58 Thousand AUD | 0.0% |
| 2016 | 36.58 Thousand AUD | -78.7% |
| 2015 | 171.78 Thousand AUD | -12.26% |
| 2014 | 195.78 Thousand AUD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | - AUD | -100.0% |
| 2024 Q4 | 239.33 Thousand AUD | 0.0% |
| 2024 Q1 | 177.02 Thousand AUD | -48.19% |
| 2024 Q2 | 290.31 Thousand AUD | 63.99% |
| 2024 FY | 239.33 Thousand AUD | -29.95% |
| 2023 Q3 | 236.69 Thousand AUD | -39.28% |
| 2023 Q4 | 341.66 Thousand AUD | 44.35% |
| 2023 Q1 | 287.78 Thousand AUD | -53.33% |
| 2023 Q2 | 389.78 Thousand AUD | 35.44% |
| 2023 FY | 341.66 Thousand AUD | -44.6% |
| 2022 Q1 | 451.09 Thousand AUD | -40.0% |
| 2022 FY | 616.66 Thousand AUD | -17.98% |
| 2022 Q4 | 616.66 Thousand AUD | 31.51% |
| 2022 Q3 | 468.91 Thousand AUD | -21.15% |
| 2022 Q2 | 594.66 Thousand AUD | 31.83% |
| 2021 FY | 751.84 Thousand AUD | -13.95% |
| 2021 Q1 | 720.04 Thousand AUD | -17.59% |
| 2021 Q2 | 814.24 Thousand AUD | 13.08% |
| 2021 Q3 | 617.22 Thousand AUD | -24.2% |
| 2021 Q4 | 751.84 Thousand AUD | 21.81% |
| 2020 Q4 | 873.68 Thousand AUD | 11.22% |
| 2020 FY | 873.68 Thousand AUD | 2287.85% |
| 2020 Q1 | 813.73 Thousand AUD | 2123.97% |
| 2020 Q2 | 930.26 Thousand AUD | 14.32% |
| 2020 Q3 | 785.54 Thousand AUD | -15.56% |
| 2019 Q2 | - AUD | 0.0% |
| 2019 Q3 | 36.58 Thousand AUD | 0.0% |
| 2019 Q4 | 36.58 Thousand AUD | 0.0% |
| 2019 FY | 36.58 Thousand AUD | 0.0% |
| 2019 Q1 | - AUD | -100.0% |
| 2018 Q1 | - AUD | -100.0% |
| 2018 Q2 | - AUD | 0.0% |
| 2018 Q3 | 36.58 Thousand AUD | 0.0% |
| 2018 FY | 36.58 Thousand AUD | 0.0% |
| 2018 Q4 | 36.58 Thousand AUD | 0.0% |
| 2017 Q1 | - AUD | -100.0% |
| 2017 FY | 36.58 Thousand AUD | 0.0% |
| 2017 Q4 | 36.58 Thousand AUD | 0.0% |
| 2017 Q3 | 36.58 Thousand AUD | 0.0% |
| 2017 Q2 | - AUD | 0.0% |
| 2016 Q1 | 36.63 Thousand AUD | -78.68% |
| 2016 Q3 | 36.58 Thousand AUD | -0.11% |
| 2016 Q4 | 36.58 Thousand AUD | 0.0% |
| 2016 Q2 | 36.63 Thousand AUD | 0.0% |
| 2016 FY | 36.58 Thousand AUD | -78.7% |
| 2015 FY | 171.78 Thousand AUD | -12.26% |
| 2015 Q1 | - AUD | 0.0% |
| 2015 Q4 | 171.78 Thousand AUD | 0.0% |
| 2014 FY | 195.78 Thousand AUD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ContraFect Corporation | 2.88 Million USD | 91.693% |
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 99.419% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 94.194% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 40.443% |
| SQZ Biotechnologies Company | 27.47 Million USD | 99.129% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 89.71% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 99.448% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 99.196% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | 74.761% |
| Marizyme, Inc. | 18.71 Million USD | 98.721% |
| Genus plc | 233.1 Million USD | 99.897% |
| Pharming Group N.V. | 171.54 Million USD | 99.86% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | 73.05% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 82.187% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | 68.089% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | 83.452% |
| IMV Inc. | 28.88 Million USD | 99.171% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 95.77% |
| ONE Bio Corp. | 19.71 Million USD | 98.786% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 99.584% |
| Neon Bloom, Inc. | 630.07 Thousand USD | 62.016% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | 80.516% |
| Biomind Labs Inc. | 735.54 Thousand USD | 67.462% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 99.646% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 98.159% |
| Skye Bioscience, Inc. | 4.61 Million USD | 94.814% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 33.466% |
| Mesoblast Limited | 118.7 Million USD | 99.798% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -69.116% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 95.924% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -830.557% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 89.403% |
| GB Sciences, Inc. | 1.75 Million USD | 86.396% |
| MultiCell Technologies, Inc. | 202.58 USD | -118040.981% |
| Alpha Cognition Inc. | 1.22 Million USD | 80.389% |
| HST Global, Inc. | 98.31 Thousand USD | -143.422% |
| CSL Limited | 12.18 Billion USD | 99.998% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Agentix Corp. | 50 Thousand USD | -378.66% |
| Halberd Corporation | 150 Thousand USD | -59.553% |
| Enzolytics Inc. | 996.33 Thousand USD | 75.979% |
| Resverlogix Corp. | 6.49 Million USD | 96.313% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | 6.362% |
| argenx SE | 20 Million USD | 98.803% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 99.277% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 1.92 Million USD | 87.567% |
| Zenith Capital Corp. | 10.22 Thousand USD | -2240.636% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 90.018% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -4.378% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -60.998% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.943% |
| Kadimastem Ltd | 891.22 Thousand USD | 73.146% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 92.091% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 98.823% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 91.833% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -76.644% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.49 Million USD | 83.989% |
| Reve Technologies, Inc. | 250.18 Thousand USD | 4.338% |
| Q BioMed Inc. | 4.1 Million USD | 94.177% |
| LadRx Corporation | 33.6 Thousand USD | -612.164% |
| Cell Source, Inc. | 9.25 Million USD | 97.414% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 68.351% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 99.475% |
| Itoco Inc. | 228.37 Thousand USD | -4.796% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -13.44% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | 3.775% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 96.616% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 95.197% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 91.164% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -19.298% |
| NovAccess Global Inc. | 2.19 Million USD | 89.121% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 4.71 Million USD | 94.92% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | 31.979% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 96.939% |
| SYBLEU INC | 477.5 Thousand USD | 49.879% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -95.371% |
| Rebus Holdings, Inc. | 310 Thousand USD | 22.797% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 68.351% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 94.946% |
| Affymax, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | 50.581% |
| International Stem Cell Corporation | 4.17 Million USD | 94.272% |
| CytoDyn Inc. | 30.07 Million USD | 99.204% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -283.462% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 89.026% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 97.122% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 97.212% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | 84.614% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | 10.698% |
| Neutra Corp. | 54.15 Thousand USD | -341.927% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 86.922% |
| PureTech Health plc | 25.51 Million USD | 99.062% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | 80.451% |
| IXICO plc | 472.02 Thousand USD | 49.297% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 98.456% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 99.616% |
| CSL Limited | 12.18 Billion USD | 99.998% |
| Cellectis S.A. | 92.77 Million USD | 99.742% |